Tests Qingre Huatan Formula to prevent worsening after acute ischemic stroke
Tests a herbal formula against placebo in adults with acute ischemic stroke.
Plain-language title generated from the registry record
Registry title: Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in hospital with an acute ischemic stroke that started within 48 hours, who are at high risk of early worsening and have a TCM phlegm-heat syndrome.
- Age
- 18 to 80 years
- Sex
- Men and women can join.
- Disease stage
- Acute ischemic stroke within 48 hours after onset, at high risk of early neurological deterioration (END): new lesions on MRI with DWI-ASPECTS score ≤ 7, or at least two risk factors of END.
- Earlier treatment
- People who received or are planned to receive thrombolysis or endovascular therapy after onset cannot join.
- Biomarker or test result
- Meets the criteria of TCM phlegm-heat syndrome. MRI shows new ischemic lesions.
Main reasons for not taking part
- Received or planned thrombolysis or endovascular therapy after onset
- Stroke thought to be caused by brain tumor, brain trauma, blood disease, etc.
- Already dependent in daily living before this stroke (modified Rankin Scale score ≥2)
- Known severe liver or kidney problems, as defined by blood test limits in the record
- Pregnancy, possible pregnancy or breastfeeding
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06857487, who can take part
Where in China
- Dongzhimen HospitalBeijing, ChinaContact: Xinxing LaiTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Dongzhimen Hospital, Beijing
- Trial code
- NCT06857487
- Record updated
- 1 December 2025
- Original description
The purpose of this study is to assess the effectiveness and safety of Qingre Huatan formula versus placebo on preventing early neurological deterioration in patients with acute ischemic stroke within 48 hours after onset.Read full original descriptionShow less
Efficacy and Safety of Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Patients With Acute Ischemic Stroke : A Randomized Double-blind Placebo-controlled Pilot Trial
The purpose of this study is to assess the effectiveness and safety of Qingre Huatan formula versus placebo on preventing early neurological deterioration in patients with acute ischemic stroke within 48 hours after onset.
Inclusion: Inpatients diagnosed with acute ischemic stroke. Inpatients diagnosed of acute ischemic stroke; Meet the criteria of TCM phlegm-heat syndrome; Patients at high-risk of END : Magnetic resonance imaging (MRI) reveals new ischemic lesions, with DWI-ASPECTS score ≤ 7, or presence of at least two risk factors of END; Acute ischemic stroke within 48 hours after onset; Aged 18-80 years, male or female; The patient or representative has signed informed consent.
Exclusion: Received or planned thrombolysis or endovascular therapy after onset; Suspected secondary stroke caused by brain tumor, brain trauma, hemopathy, etc; Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scare score ≥2 ); Diseases that cause motor dysfunction, including osteoarthritis, etc; Known severe aphasia or mental illness affecting clinical information collection and evaluation; Known severe liver or kidney dysfunction (alanine aminotransferase or aspartate transaminase > 2 times the upper limit of normal value, serum creatinine > 1.5 times the upper limit of normal value); Pregnancy, potential pregnancy or breastfeeding; Currently participating in other clinical trials.